Historique
Rapport
The funding crisis for harm reduction: Donor retreat, government neglect and the way forward
Auteur(s) :
COOK, C. ;
BRIDGE, J. ;
McLEAN, S. ;
PHELAN, M. ;
BARRETT, D.
Année
2014
Page(s) :
41 p.
Langue(s) :
Anglais
Éditeur(s) :
London : HRI (Harm Reduction International)
Domaine :
Drogues illicites / Illicit drugs
Thésaurus mots-clés
REDUCTION DES RISQUES ET DES DOMMAGES
;
FINANCEMENT
;
POLITIQUE
;
RECOMMANDATION
;
VIH
;
PREVENTION
;
DEPENSE
Thésaurus géographique
INTERNATIONAL
;
ROYAUME-UNI
;
PAYS-BAS
;
ETATS-UNIS
Résumé :
This report tells the story of HIV-related harm reduction funding over time and illustrates why an AIDS-free generation will not be possible if the present rate and pace of investment continues. It highlights the changing donor landscape and the particular problem for harm reduction funding in middle-income countries with decreasing international donor support.
While the challenges are considerable, there are concrete actions that donors, governments and harm reduction advocates can take to build a fully funded, sustainable harm reduction response.
The resources needed are minimal when compared with the level of funding invested in drug law enforcement, imprisoning those convicted of minor drug offences, and treating HIV and hepatitis C infections that could have been averted. The resources needed are minimal when the real potential to avert new HIV and hepatitis C infections and save lives is factored in.
Strategic investment in HIV programmes targeting key populations is required, regardless of country income status. Bilateral investments must be re-prioritised, and existing resources in drug policy should be rebalanced in favour of health and harm reduction.
While the challenges are considerable, there are concrete actions that donors, governments and harm reduction advocates can take to build a fully funded, sustainable harm reduction response.
The resources needed are minimal when compared with the level of funding invested in drug law enforcement, imprisoning those convicted of minor drug offences, and treating HIV and hepatitis C infections that could have been averted. The resources needed are minimal when the real potential to avert new HIV and hepatitis C infections and save lives is factored in.
Strategic investment in HIV programmes targeting key populations is required, regardless of country income status. Bilateral investments must be re-prioritised, and existing resources in drug policy should be rebalanced in favour of health and harm reduction.
Affiliation :
International Harm Reduction Association, London, UK